Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

786 - PD-L1 expression on circulating monocytes in patients with breast cancer


24 Nov 2018


Poster display - Cocktail


Pathology/Molecular Biology

Tumour Site

Breast Cancer


Mayuko Nagano


Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427


M. Nagano1, K. Saito2, Y. Kozuka3, M. Shibusawa1, N. Imai1, A. Noro1, Y. Kageyama2, T. Mizuno2, T. Ogawa1, N. Katayama2

Author affiliations

  • 1 Breast Surgery, Mie University Hospital, 514-8507 - Tsu/JP
  • 2 Hematology And Medical Oncology, Mie University Hospital, 514-8507 - Tsu/JP
  • 3 Pathology, Mie University Hospital, 514-8507 - Tsu/JP


Abstract 786


Programmed death-ligand 1 (PD-L1) expression on tumor cells has been found to predict the response to immune checkpoint inhibitors in various cancers. PD-L1 is upregulated not only in tumor cells, but also in immune cells, such as macrophages in the tumor microenvironment. It is known that macrophages differentiate from monocytes. However, there are no data about PD-L1 expression in monocytes from patients with cancer. Whether PD-L1 expression on monocytes could serve as an alternative biomarker is of great interest.


We prospectively collected peripheral blood mononuclear cells from 44 untreated patients with primary breast cancer from stage I to IV between 2016 and 2018. Flow cytometry was used to detect PD-L1 expression on monocytes.


We found that the level of PD-L1 expression on monocytes increased from patients with primary breast cancer (the median of PD-L1 stained cells was 14.0% (2.6-41.2) vs. isotype control of 1.0% (0.1-11.7), p < 0.001). The median proportions of PD-L1+ monocytes in patients with stage I, II, III, and IV cancers were 7.8% (2.6-35.5), 17.9% (4.3-41.2), 16.7% (9.6-25.9), and 25%, respectively. In lymph-node metastasis negative and positive patients, the proportions were 10.9% (2.6-41.2) and 17.9% (4.3-27.3), respectively. There were no significant differences among each stage nor between groups. However, early stages of breast cancers tended to have a lower proportion of PD-L1+ monocytes. In contrast, we observed that there was no trend between PD-L1 expression and the subtypes: HR+, 17.9% (2.6-41.2); HER2+, 16.7% (7.7-25.9); or TN, 10.7% (4.3-33.2). In addition, there was no significant correlation between the proportion of PD-L1+ monocytes and Ki-67 index (p = 0.94) of tumor cells nor %tumor infiltrating lymphocytes (TILs) (p = 0.83) in primary tumors.


We found upregulated PD-L1 levels in monocytes in untreated patients with breast cancer. The proportions of PD-L1+ cells tend to increase depending on disease progression. In contrast, there was no association between PD-L1+ cells and subtypes, proliferative index, or %TILs. These data suggest that PD-L1 expression on circulating monocytes may reflect tumor burden rather than tumor biology.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Mie University Hospital.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.